IP Library Granted Patent US 7,838,536
Granted Patent B2
US 7,838,536 · App. 12/410,392 · Granted Nov 23, 2010

Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,838,536
App. No.
12/410,392
Granted
Nov 23, 2010
Kind
B2
Abstract

Disclosed herein are novel zinc ionophores, zinc chelators and/or zinc complexes with enhanced aqueous solubility. Methods of treating cancer using at least one zinc ionophore and/or zinc chelator are also disclosed. Also disclosed herein are compositions and methods for treating cancer with combination therapy using at least one texaphyrin metal complex and at least one zinc ionophore or the respective pharmaceutically acceptable derivatives or salts thereof.

Claims (32)

1. A compound having the structure:

wherein:

each R 0 , each R 1 , each R 2 , and each R 3 is independently H, OH, NH 2 , NO 2 , CN, halogen, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl, aralkyl, substituted aralkyl, substituted amino, alkoxy, substituted alkoxy, —S -(alkyl or substituted alkyl), —S(O) k (alkyl or substituted alkyl), where k is 1, 2, or 3, —C(O)-(alkyl or substituted alkyl), —C(O)O-(alkyl or substituted alkyl), —OC(O)-(alkyl or substituted alkyl), —C(S)-(alkyl or substituted alkyl), —CON(R′)-(alkyl or substituted alkyl), —O—CON(R′)-(alkyl or substituted alkyl), —CSN(R′)-(alkyl or substituted alkyl), —N(R′)CO-(alkyl or substituted alkyl), —N(R′)C(O)O-(alkyl or substituted alkyl), —N(R′)C(O)N(R′)-(alkyl or substituted alkyl), where each R′ is independently H, alkyl, or substituted alkyl;

L 1 is —C(O)-(alkyl or substituted alkyl), —C(O)O-(alkyl or substituted alkyl), —OC(O)-(alkyl or substituted alkyl), —CON(R′)-(alkyl or substituted alkyl), alkyl, substituted alkyl, alkenyl, alkoxy, substituted alkoxy, alkylalkoxy, substituted alkylalkoxy, polyalkylene oxide, substituted polyalkylene oxide, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl, aralkyl, or substituted aralkyl;

X is —O-(alkylene or substituted alkylene)-, or —S(O) k (alkylene or substituted alkylene)-, where k is 1, 2, or 3;

each n is an integral number selected from 1 to 20; and

L 2 is selected from the group consisting of a direct bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, —O—, —O -(alkylene or substituted alkylene)-, —S—, —S-(alkylene or substituted alkylene)-, —S(O) k — where k is 1, 2, or 3, —S(O) k (alkylene or substituted alkylene)-, —C(O)—, —C(O)-(alkylene or substituted alkylene)-, —C(S)—, —C(S)-(alkylene or substituted alkylene)-, —N(R′) 2 —, —NR′-(alkylene or substituted alkylene)-, —C(O)N(R′)—, —CON(R′)-(alkylene or substituted alkylene)-, —O—CON(R′)-(alkylene or substituted alkylene)-, —CSN(R′)—, —CSN(R′) -(alkylene or substituted alkylene)-, —N(R′)CO-(alkylene or substituted alkylene)-, —N(R′)C(O)O—, —N(R′)C(O)O-(alkylene or substituted alkylene)-, —S(O) k N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)N(R′)-(alkylene or substituted alkylene)-, —N(R′)C(S)N(R′)—, —N(R′)S(O) k N(R′)—, and —C(R′) 2 —N(R′)—N(R′)—; where each R′ is independently H, alkyl, or substituted alkyl;

L is selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, —O—, —O-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-O-(alkylene or substituted alkylene)-, —O-(alkylene or substituted alkylene)-O—, —S—, —S-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-S-(alkylene or substituted alkylene)-, —S(O) k — where k is 1, 2, or 3, —S(O) k (alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-S(O) k -(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-S—S-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-O -(alkylene or substituted alkylene)-S—S-(alkylene or substituted alkylene)-O-(alkylene or substituted alkylene)-, —C(O)—, —C(O)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-C(O)-(alkylene or substituted alkylene)-, —C(S)—, —C(S)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-C(S)-(alkylene or substituted alkylene)-, —N(R′) 2 —, —NR′-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-NR′-(alkylene or substituted alkylene)-, —C(O)N(R′)—, —CON(R′)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-CON(R′)-(alkylene or substituted alkylene)-, —O—CON(R′)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-O—CON(R′)-(alkylene or substituted alkylene)-, —CSN(R′)—, —CSN(R′)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene) -CSN(R′)-(alkylene or substituted alkylene)-, —N(R′)CO-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-N(R′)CO-(alkylene or substituted alkylene)-, —N(R′)C(O)O—, —N(R′)C(O)O-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-N(R′)C(O)O-(alkylene or substituted alkylene)-, —S(O) k N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)N(R′)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-N(R′)C(O)N(R′)-(alkylene or substituted alkylene)-, —N(R′)C(S)N(R′)—, —N(R′)S(O) k N(R′)—, and —C(R′) 2 —N(R′)—N(R′)—; where each R′ is independently H, alkyl, or substituted alkyl; and pharmaceutically acceptable salts.

2. The compound of claim 1 having the structure

3. The compound of claim 2 wherein R 0 , each R 1 , each R 2 and R 3 are independently hydrogen.

4. The compound of claim 3 wherein L is selected from the group consisting of —O—, —O-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-O -(alkylene or substituted alkylene)-, and —O-(alkylene or substituted alkylene)-O—.

5. The compound of claim 4 wherein L is —O—.

6. The compound of claim 4 wherein L is —O-(alkylene or substituted alkylene)-O—.

7. The compound of claim 6 wherein alkylene is CH 2 CH 2 .

8. The compound of claim 1 having the structure

9. The compound of claim 8 wherein R 0 , each R 1 , each R 2 and R 3 are independently hydrogen.

10. The compound of claim 9 wherein L 1 is —CON(R′)-(alkyl or substituted alkyl), alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkylalkoxy, substituted alkylalkoxy, polyalkylene oxide, or substituted polyalkylene oxide.

11. The compound of claim 10 wherein L 1 is O—CH 2 CH 2 —.

12. The compound of claim 11 wherein X is —O-(alkylene or substituted alkylene)-.

13. The compound of claim 12 wherein alkylene is CH 2 CH 2 .

14. The compound of claim 13 wherein n is 1 to 5.

15. The compound of claim 14 wherein n is 1.

16. The compound of claim 14 wherein n is 2.

17. The compound of claim 14 wherein L 2 is a direct bond, alkylene, substituted alkylene, —O—, or —C(O)N(R′)—.

18. A pharmaceutical composition comprising a compound having the structure:

wherein:

each R 0 , each R 1 , each R 2 , and each R 3 is independently H, OH, NH 2 , NO 2 , CN, halogen, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl, aralkyl, substituted aralkyl, substituted amino, alkoxy, substituted alkoxy, —S— (alkyl or substituted alkyl), —S(O) k (alkyl or substituted alkyl), where k is 1, 2, or 3, —C(O) -(alkyl or substituted alkyl), —C(O)O-(alkyl or substituted alkyl), —OC(O)-(alkyl or substituted alkyl), —C(S)-(alkyl or substituted alkyl), —CON(R′)-(alkyl or substituted alkyl), —O—CON(R′)-(alkyl or substituted alkyl), —CSN(R′)-(alkyl or substituted alkyl), —N(R′)CO-(alkyl or substituted alkyl), —N(R′)C(O)O-(alkyl or substituted alkyl), —N(R′)C(O)N(R′)-(alkyl or substituted alkyl), where each R′ is independently H, alkyl, or substituted alkyl;

L 1 is —C(O)-(alkyl or substituted alkyl), —C(O)O-(alkyl or substituted alkyl), —OC(O)-(alkyl or substituted alkyl), —CON(R′)-(alkyl or substituted alkyl), alkyl, substituted alkyl, alkenyl, alkoxy, substituted alkoxy, alkylalkoxy, substituted alkylalkoxy, polyalkylene oxide, substituted polyalkylene oxide, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl, aralkyl, or substituted aralkyl;

X is —O-(alkylene or substituted alkylene)-, or —S(O) k (alkylene or substituted alkylene)-, where k is 1, 2, or 3;

each n is an integral number selected from 1 to 20; and

L 2 is selected from the group consisting of a direct bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, —O—, —O -(alkylene or substituted alkylene)-, —S—, —S-(alkylene or substituted alkylene)-, —S(O) k —where k is 1, 2, or 3, —S(O) k (alkylene or substituted alkylene)-, —C(O)—, —C(O)-(alkylene or substituted alkylene)-, —C(S)—, —C(S)-(alkylene or substituted alkylene)-, —N(R′) 2 —, —NR′-(alkylene or substituted alkylene)-, —C(O)N(R′)—, —CON(R′)-(alkylene or substituted alkylene)-, —O—CON(R′)-(alkylene or substituted alkylene)-, —CSN(R′)—, —CSN(R′) -(alkylene or substituted alkylene)-, —N(R′)CO-(alkylene or substituted alkylene)-, —N(R′)C(O)O—, —N(R′)C(O)O-(alkylene or substituted alkylene)-, —S(O) k N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)N(R′)-(alkylene or substituted alkylene)-, —N(R′)C(S)N(R′)—, —N(R′)S(O) k N(R′)—, and —C(R′) 2 —N(R′)—N(R′)—; where each R′ is independently H, alkyl, or substituted alkyl;

L is selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, —O—, —O-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-O-(alkylene or substituted alkylene)-, —O-(alkylene or substituted alkylene)-O—, —S—, —S-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-S-(alkylene or substituted alkylene)-, —S(O) k — where k is 1, 2, or 3, —S(O) k (alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-S(O) k -(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-S—S-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-O -(alkylene or substituted alkylene)-S—S-(alkylene or substituted alkylene)-O-(alkylene or substituted alkylene)-, —C(O)—, —C(O)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-C(O)-(alkylene or substituted alkylene)-, —C(S)—, —C(S)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-C(S)-(alkylene or substituted alkylene)-, —N(R′) 2 —, —NR′-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-NR′-(alkylene or substituted alkylene)-, —C(O)N(R′)—, —CON(R′)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-CON(R′)-(alkylene or substituted alkylene)-, —O—CON(R′)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-O—CON(R′)-(alkylene or substituted alkylene)-, —CSN(R′)—, —CSN(R′)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene) -CSN(R′)-(alkylene or substituted alkylene)-, —N(R′)CO-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-N(R′)CO-(alkylene or substituted alkylene)-, -N(R′)C(O)O—, —N(R′)C(O)O-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-N(R′)C(O)O-(alkylene or substituted alkylene)-, —S(O) k N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)N(R′)-(alkylene or substituted alkylene)-, -(alkylene or substituted alkylene)-N(R′)C(O)N(R′)-(alkylene or substituted alkylene)-, —N(R′)C(S)N(R′)—, —N(R′)S(O) k N(R′)—, and —C(R′) 2 —N(R′)—N(R′)—; where each R′ is independently H, alkyl, or substituted alkyl; and pharmaceutically acceptable salts and a pharmaceutically acceptable excipient thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2010
From: PHARMACYCLICS, INC.
To: SESSLER, JONATHAN L.
Reel/Frame 025145/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2010
From: MAGDA, DARREN; SESSLER, JONATHAN
To: PHARMACYCLICS, INC.
Reel/Frame 025145/0839 →